all

The NLA held a consensus conference in January 2011 to bring together experts on inflammatory markers and advanced lipoprotein testing for the generation of an NLA statement of clinical guidance regarding the utility of various biomarkers. The panel reviewed apolipoprotein B (Apo B), C-reactive protein (CRP), high-density lipoprotein (HDL) subfractions, lipoprotein-associated phospholipase A2 (Lp-PLA2), low-density lipoprotein (LDL) subfractions, low-density lipoprotein particle number/concentration (LDL-P), and lipoprotein (a) (Lp(a)).

Click here to view the manuscript. 

Adapted from an article in the Journal of Clinical Lipidology (JCL) titled, The Importance of Non-HDL Cholesterol Reporting in Lipid Management¹

MIAMI, Fla. – (May 17, 2019) -- The National Lipid Association (NLA) today announced the release of an official scientific statement on Lipoprotein(a) [Lp(a)] clinical use at the NLA 2019 Scientific Sessions, May 16 – 19 at the Turnberry Isle Miami in Aventura, Florida.

Created by an international team of clinical lipid experts (see list on page 2), the statement is designed as a comprehensive source of guidance for medical professionals making decisions to improve the health and well-being of children and adults at risk of premature cardiovascular disease.